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Abstract
Background: The aim of this study is to see how the sutureless, stentless, Perceval S aortic valves behave when
implanted in elderly patients with small aortic root and the comparison with a second group of patients with
similar characteristics where a conventional stented bioprosthesis was implanted. This is a prospective randomized
institutional study.
Methods: Our material is composed from 25 patients who underwent aortic valve replacement with sutureless self-
anchoring Perceval S valve implantation (LivaNova), compared with 25 patients with conventional stented
biological prosthesis implanted (soprano LivaNova group). The two groups of patients have similar demographic
and medical characteristics with severe aortic stenosis. The study was conducted from January 2012 to June 2014.
Preoperative, intraoperative and postoperative parameters were studied in order to investigate the utility of the
Perceval S valves in this group of patients.
Results: The Perceval S valve implantation seems to be an interesting biological valve with good hemodynamic
characteristics as compared with the typical biological prosthesis providing shorter ischemia time (40 ± 5.50 min vs
86 ± 15.86 min; p < 0.001), shorter extracorporeal circulation time (73.75 ± 8.12 min vs 120.36 ± 28.31 min p < 0.001),
less operation time (149.38 ± 15.22 min vs 206.64 ± 42.85 min; p < 0.001) and better postoperative recovery. The
postoperative gradients were 23.5 ± 19.20 mmHg vs 24.5 ± 19.90 mmHg respectively. The postoperative effective
orifice area in these two groups were respectively 1.5 =/-0.19 cm2 vs 1.1=/-0.5 cm2 (p 0.002). Among the 25
patients of the Soprano stented valve, 3 (12 %) came back in 6 months with New York Heart Association (NYHA) 3.
The PPM of these patients was the cause of readmission in the Hospital required diuresis and supplementary
treatment.
Conclusions: Aortic valve replacement with Perceval aortic valves in geriatric patients with comorbidities and small
aortic annulus seems to be an alternative, safe and “fast” intervention with excellent short and mid-term results
which provides a better effective orifice area.
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Background
The sutureless Perceval bioprosthesis (LivaNova Biomedica
Cardio Srl, Sallugia, Italy) was designed in order to obtain
the hemodynamic benefits of the stentless valves without
the increased difficulty in surgical implantation [1]. This
valve is a bioprosthesis comprising a bovine pericardium
tissue valve attached to a self-expanding anchoring device
(Fig. 1), which has the dual role of supporting the biopros-
thetic valve and offering fixation to the implantation site in
the native aortic annulus [1]. As a result of the sutureless
implant procedure, patients could benefit from reducing
aortic cross-clamp time, with subsequent overall reduction
of the surgical duration and reduction in related risks by
avoiding passing the stitches through the calcified annulus
and sutures knotting, with subsequent less risk of tearing
the annulus and aortic wall or embolizing the systematic
circulation [2]. In a small and calcified annulus it can be
challenging to insert a stented valve and a significant re-
sidual gradient is frequently observed afterwards. Stentless
valves are designed in order to overcome some of the disad-
vantages of the stented valves [1, 3, 4]. This device with its
three button holes provides the correct positioning of the
valve in the native aortic root (Fig. 2). In order to minimize
or avoid the paravalvular leakage, the Perceval S valve is
designed with an intra–annular and a supra–annular
sealing collar (Fig. 3). This device is the ideal solution for
elderly patients who require a rapid procedure and for
patients with small aortic root which require root enlarge-
ment. As known, an aortic root enlargement (Nikcs-Nunez
or Manougian technique) may be necessary in small annu-
lus in order to avoid a “patients-prosthesis mismatch” [5].
This operation is challenging in elderly patients with
comorbidities and heavily calcified aorta which a rapid
intervention is necessary. The prosthetic implant is sup-
ported by dedicated tools: crimping system, manometer
and dilatation balloon (Fig. 4). Prior to its implantation the
prosthesis diameter is reduced to a suitable size, using the
Perceval S collapsing tool, and then loaded on the Perceval
S special holder (Fig. 5). After in situ positioning the valve
is released in two steps: first the inflow ring is released at
the native aortic annulus level and then, when proper posi-
tioning is verified, the complete prosthesis release is
achieved (Fig. 6). After the implantation the Perceval S
post-dilation balloon catheter is inflated inside the pros-
thesis at the inflow level to improve apposition by modeling
the inflow ring on the native annulus [1, 6, 7]. In vitro ac-
celerated fatigue tests were performed under normal and
hypertensive conditions. These tests demonstrated that the
whole device remains functional up to 900 Million cycles
(more than 20 year of normal equivalent life). These results
exceed the minimal ISO and FDA requirements and
suggest a wide safety margin of the Perceval S bioprosthesis
[1, 7]. We report our experience with the Perceval S
Fig. 1 The Perceval S aortic valve is a bioprosthesis comprising a
bovine pericardium tissue valve attached to a self-expanding
anchoring device
Fig. 2 This device through its three button holes provides the
correct positioning of the valve in the native aortic root
Fig. 3 In order to minimize or avoid the paravalvular leakage, the
Perceval S valve is designed with an intra–annular and a supra–annular
sealing collar
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bioprosthesis implanted onto 25 elderly with small aortic
annulus and low BSA and we compared this group with 25
similar patients receiving conventional stented bioprosth-
esis. Our study is conducted in order to investigate two end
points: effectiveness and performance so we will basically
see its hemodynamic profile and its impact on effective ori-
fice area other than the whole clinical outcome of the pa-
tients in the early postoperative period (within a month
following surgery).
Methods
In our study 25 sutureless self-anchoring, Perceval S,
(LivaNova Biomedica Cardio Srl, Sallugia, Italy) valves are
compared with 25 conventional biological stented pros-
thesis (soprano- Sorin Group) implanted onto similar
characteristic patients with severe aortic stenosis. The
study was conducted from January 2012 to June 2014. Pa-
tients were randomized divided into groups and they have
previously consented for either method of surgical treat-
ment. Randomization was done via a computerized
assisted mathematic model. The inclusion criteria were
defined as to see how the elderly patients with small aortic
root and low BSA who are the real life difficult patients,
will benefit from the use of a novel sutureless self-
anchoring biological prosthesis. Limitations of this study
were defined in a country with strict economic environ-
ment. The mean EuroSCORE II was 9.5 ± 3.5 in the Perce-
val group and 9.9 ± 3.6 in the conventional group. The
BSA in m2 was 1.45 ± 1.2 and 1.78 ± 1.1. The rest patient’s
characteristics are showing in the Table 1. The
hemoglobin level was 33.3 g/L in the Perceval S group
and 32.8 in the Soprano stented group preoperatively.
Then, postoperatively, the hemoglobin was 28.6 in the
Perceval S group and 28.8 in the second group. So, we did
not find any statistically significate difference between the
groups. All patients were treated with median full sternot-
omy, routine cannulation to the extracorporeal circulation
with Edwards aortic cannula at the distal part of the as-
cending aorta and a two-stage venous cannula at the right
atrium. Retrograde cardioplegia plus elective cardioplegia
to the right coronary artery (ARC) was given in all pa-
tients. There was just one initial dose of cardioplegia given
to all patients accompanying by local cooling with ice
slush. No systematic extra cooling was required in our
patients. The cross clamp was applied as distal as possible
and aortotomy was performed approximately 2 cm above
the sino-tubular junction (STJ). For the cases of conven-
tional stented valve implantation an extension of the aor-
totomy towards the non-coronary sinus was performed.
Fig. 4 The prosthetic implant is supported by dedicated tools:
crimping system, manometer and dilatation balloon
Fig. 5 Prior to its implantation the prosthesis diameter is reduced to
a suitable size, using the Perceval S collapsing tool, and then loaded
on the Perceval S special holder
Fig. 6 Using the three guides it performs in situ positioning of the
valve. It is released in two steps: first the inflow ring is released at
the native aortic annulus level and then, when proper positioning is
verified, the complete prosthesis release is achieved





Number of patients 25 25
Age (mean) 80 ± 3.3 79 ± 4.1
Sex (♀/total) 15/25 11/25
Euro Score II 9.5 ± 3.5 9.9 ± 3.6
BSA (m2) 1.45 ± 1.2 1.78 ± 1,1
Stroke history 2/25 (8 %) 1/25 (4 %)
Preop rhythm 2/25 rbbb, 1/25 lbbb,
16/25 NSR, 1/25 A-F




1/25 (2 grafts) 2/25 (1 graft each)
BSA body surface area, CAD coronary artery disease, CABG coronary artery
bypass graft
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Pledged interrupted inverted stiches were met for the
stented valve suturing. This is a prospective randomized
study. From our study were excluded patients with previous
cardiac surgery (redo operations), patients with aortic in-
sufficiency, large aortic root (> or = 30 mm), sino-tubular
junction periphery/height from the annulus > or = 1.3. Also,
patients with BSA > or = 2 m2 and patients younger than
75 years old were excluded from our study.
Ethical approval for this clinical study was obtained by our
Hospital (General Hospital of Athens), Scientific Committee.
Results
No structural prosthesis deterioration, valve thrombosis,
or significant transvalvular aortic regurgitation occurred
during the study period. There were no cases of tilting
or migration once appropriately inserted during the en-
tire study. This sutureless bioprosthesis appears to be
ideal for patients with severe calcification of the aortic
root and patients requiring concomitant procedures in
whom a reduced bypass time is mandatory [1]. Cross
clamp time and cardio-pulmonary bypass (CPB) time are
reported at Table 2. All echo-cardiographic measure-
ments were assessed by transthoracic echo. The annulus
size was between 21 and 30 mm. We have implanted 18
perceval S valves size small, five medium and two large.
In the conventional group we implanted 18 Soprano
stented valves of the 21 mm and 4 Soprano stented
valves of 20 mm. Postoperative EOA was 1.5 ± 0.3 cm2
in the Perceval group vs 1.1 ± 0.5 in the conventional
group (p 0.002). The mean EOA index was 1.034 in the
Perceval S group, while in the conventional group the
EOA index was 0.617. This is the reason why three of
the patients with Soprano stented valve came back in
6 months with New York Heart Association (NYHA) 3.
The PPM of these patients was the cause of readmission
in the Hospital required diuresis and supplementary
treatment. This is the most important result coming out
from our study. Operation time, CPB time and cross
clamp time were significantly lower in the Perceval
group (p < 0.001) as we could see in Table 2. These data
are very important in cardiac surgery procedure and es-
pecially in elderly with comorbidities. The postoperative
echo measurements were made within a month of
period following surgery.
Conclusions
We studied the behavior of the Perceval S sutureless stent-
less bioprosthesis in patients with small aortic annulus,
small BSA and older than 75 years. It seems that this is the
target group of this valve. This group of patients with co-
morbidities and calcified aorta needs a rapid operation with
minimal aortic manipulation. Age itself is not a contraindi-
cation to conventional surgery but comorbidities such as
low ejection fraction, renal dysfunction and calcified aorta
are major risk factor for mortality and morbidity [1, 8]. Ac-
cording the international bibliography [9], cross clamp time
is an independent predictor of mortality and morbidity in
low and high-risk cardiac patients. They found that pro-
longed aortic cross clamp time significantly correlated with
worse clinical outcomes. The spectrum of complications in-
cluded in-hospital mortality, prolonged hospitalization, pro-
longed ventilation, low cardiac output, higher requirements
for blood transfusion and renal complications. In Perceval
group patients, cross clamp time is significantly shorter
Table 2 Peroperative date and results
SVP (25) sutureless valve BVP (25) classic biological
valve (soprano)
P value
Number of patients 25 25
Preop. max gradient 88 ± 10.5 89 ± 12.5
Postop. max gradient 23.5 ± 19.20 mmHg 24.5 ± 19.90 mmHg 0.670
Preop EOA 0.45 ± 0.19 0.47 ± 0.21
Postop ΕΟΑ 1.5 ± 0.3 cm2 1.1 ± 0.5 cm2 0.002
Operation time 149.38 ± 15.22 min 206.64 ± 42.85 min p < 0.001
CPB time 73.75 ± 8.12 min 120.36 ± 28.31 min p < 0.001




Postoperative intubation time 6 ± 1.5 h 7 ± 1 h
ICU stay 15 ± 3.5 h 16 ± 4 h
Hospital stay 8 ± 1.5 days 7 ± 1.8 days
Postop follow-up 8 ± 1.5 months 8 ± 1.8 months
Death 0/25 1/25 arhythmia
Comparison of the two groups of patients. EOA effective orifice area, ICU intensive care unit
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than conventional group. This is an important advantage of
this valve. Patients with low left ventricle ejection fraction
(LVEF) are also candidates for this valve in order to implant
rapidly an aortic valve without long ischemic time and con-
sequently myocardial injuries. Due to the changing popula-
tion demographics, the age of the patients presenting for
AVR is also increasing [10]. A smaller-sized prosthetic valve
may result in so-called patient-prosthesis mismatch (PPM).
Therefore, different options have been proposed for pa-
tients with small aortic root presenting for AVR [5, 10].
Aortic root enlargement in elderly patients with heavily
calcified aorta and comorbidities is a challenging operation
with prolonged cross clump time and possible complica-
tions intra and postoperatively. In our opinion, old patients
with renal dysfunction or history of cerebrovascular dis-
eases may benefit from this kind of operation due to dimin-
ished operation time and less aortic manipulation. This
valve may enable a broader application of minimally inva-
sive AVR. Further longer-term experience is needed to
determine the potential clinical benefits and durability of
the Perceval S self-anchoring valve [10]. In case of valve
malposition, there is the possibility of removal and re-
implantation according the literature [11]. The valve im-
plantation is possible with partial “j” sternotomy at the third
or fourth intercostal space [12] in order to minimize the
chest wall trauma and the risk of chest instability or infec-
tion. The studies and the international bibliography confirm
the safety, efficacy, and ease of insertion of Perceval valves
in elderly patients with small annulus [13–15]. As these
valves do not need to be ‘sutured’, shorter cross-clamp and
CPB times are possible. Moreover, due to the absence of a
sewing ring, these valves are also almost ‘stentless’, with a
greater valve EOA for any given size. This may therefore re-
sult in better hemodynamic even without the root
enlargement [10]. According the literature [6], Perceval S
valve could be implanted in elderly patients who require
concomitant cardiac operation in order to minimise the op-
eration time. Sutureless valves may be advantageous com-
pared to transcatheter valve implantations as concomitant
procedures other than percutaneous coronary artery angio-
plasty are not always possible in the latter [6, 15]. Accord-
ing our results, patients older than 75 years, with small
aortic annulus and small BSA may benefit from a Perceval
S aortic valve implantation. The limitation of our study is
the small number of patients that were randomized into the
two groups. However it is practically very difficult to study a
large group of patients with the same characteristics in a
single center. There is a large multicenter randomized trial
going on and the results are expected with great interest. At
the present time, the Perceval S prosthesis has been investi-
gated in three clinical studies: 1. The “PERCEVAL TRIAL-
Perceval S valve pilot trial-v10601”, 2. The “PERCEVAL
Pivotal Trial – v10801”, 3. The “CAVALIER – Perceval S
valve clinical trial for extended CE mark-TPS001” [7].
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